Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma

被引:124
|
作者
Sugiura, Teiichi [1 ]
Uesaka, Katsuhiko [1 ]
Kanemoto, Hideyuki [1 ]
Mizuno, Takashi [1 ]
Sasaki, Keiko [2 ]
Furukawa, Hiroyoshi [3 ]
Matsunaga, Kazuya [1 ]
Maeda, Atsuyuki [1 ]
机构
[1] Shizuoka Canc Ctr, Div Hepatobiliary Pancreat Surg, Shizuoka 4118777, Japan
[2] Shizuoka Canc Ctr, Div Pathol, Shizuoka 4118777, Japan
[3] Shizuoka Canc Ctr, Div Diagnost Radiol, Shizuoka 4118777, Japan
关键词
Pancreatic cancer; CA19-9; Early recurrence; GEMCITABINE-BASED CHEMORADIATION; COMPUTED-TOMOGRAPHY; RESECTABLE ADENOCARCINOMA; BILIARY DRAINAGE; TUMOR-MARKER; CA-19-9; SURVIVAL; CHEMOTHERAPY; CANCER; THERAPY;
D O I
10.1007/s11605-012-1859-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To evaluate the preoperative factors predictive of postoperative early recurrence in patients with resected pancreatic cancer focusing on the serum CA19-9 value. One hundred fifty-four patients undergoing surgical resection for pancreatic cancer were enrolled in this study. Univariate and multivariate analyses were performed to determine the predictors of early recurrence which was defined as relapse within 6 months after surgery. On ROC curve analysis, the cutoff value of CA19-9 was determined to be 100 U/ml. Of 73 patients with CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml, 39 (53 %) had early recurrence. In contrast, only 9 of 81 patients (11 %) with CA19-9 value < 100 U/ml developed a recurrence at an early period (p < 0.001). Multivariate analysis revealed that CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml (odds ratio, 11.2) were significant predictors of early recurrence. The overall 3- and 5-year survival rates and median survival times were 47.3 %, 40.1 %, and 31 months in patients with CA19-9 value < 100 U/ml and 21.2 %, 9.4 %, and 16 months in patients with CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml (p < 0.001). A preoperative CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml was a significant predictor of early recurrence and a poor prognosis after resection for pancreatic adenocarcinoma.
引用
收藏
页码:977 / 985
页数:9
相关论文
共 50 条
  • [1] Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma
    Teiichi Sugiura
    Katsuhiko Uesaka
    Hideyuki Kanemoto
    Takashi Mizuno
    Keiko Sasaki
    Hiroyoshi Furukawa
    Kazuya Matsunaga
    Atsuyuki Maeda
    Journal of Gastrointestinal Surgery, 2012, 16 : 977 - 985
  • [2] Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma
    Hong, Sarang
    Song, Ki Byung
    Hwang, Dae Wook
    Lee, Jae Hoon
    Lee, Woohyung
    Jun, Eunsung
    Kwon, Jaewoo
    Park, Yejong
    Park, Seo Young
    Kim, Naru
    Shin, Dakyum
    Kim, Hyeyeon
    Sung, Minkyu
    Ryu, Yunbeom
    Kim, Song Cheol
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2021, 13 (11): : 1423 - 1435
  • [3] Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer
    Asaoka, Tadafumi
    Miyamoto, Atsushi
    Maeda, Sakae
    Tsujie, Masanori
    Hama, Naoki
    Yamamoto, Kazuyoshi
    Miyake, Masakazu
    Haraguchi, Naotsugu
    Nishikawa, Kazuhiro
    Hirao, Motohiro
    Ikeda, Masataka
    Sekimoto, Mitsugu
    Nakamori, Shoji
    PANCREATOLOGY, 2016, 16 (03) : 434 - 440
  • [4] Preoperative CA19-9 levels predict disease-free survival and overall survival in pancreatic adenocarcinoma patients after resection
    Guan, Shasha
    Chen, Yang
    Han, Quanli
    Deng, Guochao
    Wang, Yanrong
    Shi, Yan
    Dai, Guanghai
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (03) : 811 - +
  • [5] Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study
    Dong, Qian
    Yang, Xiang-hong
    Zhang, Yao
    Jing, Wei
    Zheng, Li-qiang
    Liu, Yun-peng
    Qu, Xiu-juan
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12
  • [6] Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma
    Ermiah, Eramah
    Eddfair, Mona
    Abdulrahman, Othman
    Elfagieh, Mohamed
    Jebriel, Abdalla
    Al-Sharif, Mona
    Assidi, Mourad
    Buhmeida, Abdelbaset
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 17 (02)
  • [7] Accuracy of preoperative serum CA19-9 levels in predicting the resectability of patients with pancreatic adenocarcinoma
    Ying Li
    Xiaojuan Yang
    Zhanzhan Zhang
    Xiaoning Kang
    Shanglong Liu
    OncologyandTranslationalMedicine, 2018, 4 (01) : 6 - 9
  • [8] Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection
    Hosokawa, Yuichi
    Nagakawa, Yuichi
    Sahara, Yatsuka
    Takishita, Chie
    Katsumata, Kenji
    Tsuchida, Akihiko
    DIGESTIVE SURGERY, 2017, 34 (02) : 125 - 132
  • [9] A combination of platelet-to-lymphocyte ratio and carbohydrate antigen 19-9 predict early recurrence after resection of pancreatic ductal adenocarcinoma
    Ikuta, Shinichi
    Sonoda, Takashi
    Aihara, Tsukasa
    Yamanaka, Naoki
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (18)
  • [10] A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer
    Liu, Liang
    Xu, Huaxiang
    Wang, Wenquan
    Wu, Chuntao
    Chen, Yong
    Yang, Jingxuan
    Cen, Putao
    Xu, Jin
    Liu, Chen
    Long, Jiang
    Guha, Sushovan
    Fu, Deliang
    Ni, Quanxing
    Jatoi, Aminah
    Chari, Suresh
    McCleary-Wheeler, Angela L.
    Fernandez-Zapico, Martin E.
    Li, Min
    Yu, Xianjun
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (09) : 2216 - 2227